Significant Incidental Findings

As the National Lung Cancer Screening Programme in the Czech Republic continues to evolve, the focus is expanding beyond tumor detection to the management of significant incidental findings. Specifically, the Czech screening framework is currently developing recommended clinical guidelines for Interstitial Lung Abnormalities (ILA) to ensure standardized care for patients identified during Low-Dose CT (LDCT) scans.

Intersticial Lung Abnormalities

Intersticial Lung Abnormalities are CT findings that may correspond to Interstitial Lung Disease (ILD) in individuals who are currently asymptomatic. In lung cancer screening cohorts globally, the prevalence of ILA is estimated at 3–10 %, making these findings even more frequent than lung cancer itself.

Recent Data

Recent data from the National Screening Centre (ÚZIS ČR) provides a clear foundation for these new guidelines. Between January 2023 and August 2025, out of 16,995 patients who underwent baseline LDCT examinations, 72 % (12,226 patients) had at least one incidental finding recorded.

Specifically regarding lung health and comorbidities:

• 3 % of patients were diagnosed with pulmonary fibrosis.
• 27 % presented with pulmonary emphysema.
• 9 % showed signs of bronchiectasis.
• 55 % were found to have coronary artery calcification.

Protocols

The Czech Republic’s initiative to establish formal ILA management protocols ensures that patients at risk of progression receive timely monitoring.

Read More